MWP
KZR

Meridian Wealth Partners’s Kezar Life Sciences KZR Stock Holding History

Meridian Wealth Partners’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-23
Closed -$1K – 723
2021
Q1 		$1K Buy
+23
New +$1.34K ﹤0.01% 1190

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Meridian Wealth Partners's KZR Position: Q2 2021 in Review

Meridian Wealth Partners sold out of Kezar Life Sciences (KZR) in Q2 2021, closing a stake of 23 shares — an estimated $1K sold.

Meridian Wealth Partners first reported a position in KZR in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 75 funds tracked by Wall St. Rank hold KZR as of Q2 2021.

  • Meridian Wealth Partners reported no remaining Kezar Life Sciences position as of Q2 2021 after selling out during the quarter.
  • Meridian Wealth Partners sold 23 Kezar Life Sciences shares in Q2 2021, an estimated $1K.
  • Meridian Wealth Partners first reported a position in Kezar Life Sciences in Q1 2021 and held it in 1 quarter.
  • Meridian Wealth Partners's Kezar Life Sciences position peaked at $1K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2021.

Based on Meridian Wealth Partners's 13F filing for Q2 2021, filed 12 Aug 2021.